Scientists Map How Tumours Push Immune Cells Into Exhaustion

Inside tumours, some of the body’s most powerful defenders gradually lose the ability to fight. These immune cells, known as T cells, are normally capable of recognizing and destroying cells that have turned cancerous. Yet when they remain in the hostile environment of a growing tumour for prolonged periods, they undergo a profound functional decline that immunologists call T cell exhaustion. A new review published in Experimental & Molecular Medicine examines how this state develops within the tumour microenvironment, why exhausted T cells often fail to respond to cancer immunotherapies, and what strategies might restore their anti-tumour power. The work arrives at a moment when understanding exhaustion has become central to the future of cancer treatment.

T cell exhaustion was first characterized in the context of chronic viral infections, where researchers observed that T cells exposed to persistent antigen stimulation lost their ability to produce key inflammatory molecules such as interleukin-2 and tumour necrosis factor. Over time, these cells also lost cytotoxic function, the very machinery they use to kill infected or malignant cells. Cancer, particularly solid tumours, creates a similar situation of chronic antigen exposure. Tumour cells continuously present mutated or overexpressed proteins that T cells can recognize, but instead of a swift, decisive attack, the interaction stretches into months or years. This perpetual stimulation, combined with a suppressive tissue environment, drives T cells into increasingly dysfunctional states.

The tumour microenvironment amplifies this process through multiple converging pressures. Solid tumours are frequently hypoxic, meaning oxygen levels are low, which restricts the metabolic activity T cells require to sustain an energetic response. Nutrient competition is fierce, as rapidly dividing cancer cells consume glucose and amino acids such as glutamine, leaving T cells starved of fuel. Lactic acid secreted by tumours acidifies the surroundings and further impairs immune metabolism. On top of these metabolic constraints, tumour cells and associated stromal cells release immunosuppressive signalling molecules, including transforming growth factor beta and prostaglandins, while recruiting regulatory T cells and myeloid-derived suppressor cells that actively dampen immune attack. Each of these forces contributes to the progressive erosion of T cell function.

A crucial insight from recent research is that exhaustion is not a single uniform state but a spectrum of differentiation. Studies using single-cell RNA sequencing and T cell receptor tracking have revealed that exhausted populations contain both progenitor-like cells and terminally exhausted cells. Progenitor exhausted T cells retain a limited capacity to proliferate and can persist over time, serving as a reservoir from which other exhausted cells arise. Terminal exhausted cells, by contrast, are locked into a dysfunctional program marked by the loss of proliferative potential and reduced effector cytokine production. This distinction matters enormously for therapy, because checkpoint blockade immunotherapies appear to depend heavily on reinvigorating the progenitor compartment rather than resurrecting the terminal cells directly.

Central to the molecular identity of exhausted T cells is the transcription factor TOX, which becomes highly expressed as exhaustion deepens. TOX does not act alone; it works within broader gene regulatory networks that reshape the cell’s identity. Exhausted T cells express inhibitory receptors such as PD-1, TIM-3, LAG-3 and TIGIT on their surface, which serve as markers of the exhausted state and, in some cases, actively transmit suppressive signals. They also shift their metabolic profile, relying more heavily on fatty acid oxidation and oxidative phosphorylation rather than the glycolytic metabolism that characterizes robustly activated T cells. These changes are not merely consequences of a hostile environment; they reflect a fundamental reprogramming of cellular identity.

That reprogramming is epigenetic in nature, and this is one of the most consequential findings in the field. Exhausted T cells accumulate stable chromatin modifications that lock in their dysfunctional gene expression patterns. Enhancer regions that once supported the expression of effector molecules are remodelled and silenced, while new regulatory elements are opened to sustain inhibitory receptor expression. The result is a state that resists simple reversal. Even when the source of chronic antigen stimulation is removed, exhausted T cells often fail to return to their original functional program, because the epigenetic landscape that governed it has been irreversibly altered. This epigenetic rigidity helps explain why some patients respond spectacularly to immune checkpoint inhibitors while others derive little benefit.

Immune checkpoint blockade, exemplified by antibodies against PD-1 and CTLA-4, has transformed the treatment of melanoma, lung cancer, kidney cancer and several other malignancies. These therapies work in part by interrupting the inhibitory signals that exhaust T cells receive. Yet the overall response rates across cancer types remain far from universal, and the review underscores that the depth of exhaustion within a patient’s tumour infiltrating lymphocytes is a major determinant of success. Tumours with abundant progenitor exhausted T cells that still retain proliferative capacity tend to respond better, whereas tumours dominated by terminal exhaustion or lacking T cell infiltration altogether, sometimes described as cold tumours, respond poorly. This understanding has fuelled efforts to combine checkpoint inhibitors with other interventions that can broaden and deepen immune responses.

Among the most promising strategies is the combination of checkpoint blockade with therapies that reshape the tumour microenvironment itself. Agents that block transforming growth factor beta signalling, deplete regulatory T cells, or reprogramme myeloid suppressor cells may relieve some of the pressures driving exhaustion in the first place. Metabolic interventions, such as drugs that improve oxygen delivery or alter nutrient availability, represent another frontier. Oncolytic viruses and radiation therapy can convert cold tumours into inflamed ones by releasing tumour antigens and provoking innate immune activation, drawing fresh waves of T cells into the tumour that have not yet undergone exhaustion. Adoptive cell therapies, including chimeric antigen receptor T cells and tumour infiltrating lymphocyte therapy, introduce freshly armed immune cells but face the same risk of becoming exhausted once they encounter the suppressive tumour milieu, prompting efforts to engineer them with enhanced fitness and resistance to suppression.

Looking ahead, the review highlights the potential of manipulating the epigenetic and transcriptional programs that define exhaustion. Drugs targeting DNA methylation and histone modification are already approved for certain cancers, and researchers are investigating whether such agents can loosen the epigenetic locks that keep exhausted T cells dysfunctional. More precise approaches may one day selectively reprogramme the enhancer landscape of exhausted T cells, restoring effector function while preserving the cells’ tumour specificity. Single-cell and spatial profiling technologies continue to refine the map of exhaustion states within tumours, enabling clinicians to stratify patients according to the immunological character of their disease and to monitor how therapies shift T cell states over time.

Decoding T cell exhaustion in the tumour microenvironment is ultimately about recovering a lost weapon. The immune system already possesses cells capable of eliminating cancer; the challenge is that tumours have learned to wear them down through chronic stimulation and environmental hostility. By dissecting the transcriptional, epigenetic and metabolic architecture of exhaustion, researchers are converting what once seemed like an irreversible defeat into a set of addressable molecular mechanisms. Each layer of understanding brings the field closer to combination therapies that can prevent exhaustion, reverse it in its earlier stages, or work around it when it has become entrenched, offering new hope for patients whose cancers have so far resisted the immune system’s grasp.

Subject of Research: T cell exhaustion in the tumour microenvironment and its implications for cancer immunotherapy

Article Title: Decoding T cell exhaustion in the tumour microenvironment

Article References: Park, J. A., Im, J., & Hwang, S.-M. (2026). Decoding T cell exhaustion in the tumour microenvironment. Experimental & Molecular Medicine, 58(8), 2590-2602. https://doi.org/10.1038/s12276-026-01809-w

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01809-w

Keywords: T cell exhaustion, tumour microenvironment, immunotherapy, PD-1, checkpoint blockade, TOX, epigenetics, cancer, inhibitory receptors, single-cell sequencing, Decoding, cell